HF
BOLT icon

HRT Financial’s Bolt Biotherapeutics BOLT Stock Holding History

HRT Financial’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,738
Closed -$70K – 2823
2022
Q2 		$70K Buy
1,738
+784
+82% +$30.4K ﹤0.01% 2478
2022
Q1 		$52K Sell
954
-1,625
-63% -$109K ﹤0.01% 2742
2021
Q4 		$252K Buy
+2,579
New +$490K ﹤0.01% 2379

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

HRT Financial's BOLT Position: Q3 2022 in Review

HRT Financial sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 1,738 shares — an estimated $70K sold.

HRT Financial first reported a position in BOLT in Q4 2021 and held it in 3 quarters. The position peaked at $252K in Q4 2021. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • HRT Financial reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • HRT Financial sold 1,738 Bolt Biotherapeutics shares in Q3 2022, an estimated $70K.
  • HRT Financial first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 3 quarters.
  • HRT Financial's Bolt Biotherapeutics position peaked at $252K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on HRT Financial's 13F filing for Q3 2022, filed 14 Nov 2022.